The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.
Schizophrenia affects about 1 percent of the U.S. population, ages 18 years and older, in a given year. The most prominent symptoms include hallucinations, delusions, disordered thinking and behavior, and suspiciousness. Hearing voices that other people don't hear is the most common type of hallucination. These experiences can make people with the disorder fearful and withdrawn.
“Schizophrenia can be a devastating illness requiring lifelong treatment,” said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research. “Some patients do not respond well to certain types of drug therapy, so it is important to have multiple treatment options available.”
Latuda is included in the atypical antipsychotic class of drugs. All atypical antipsychotics contain a boxed warning alerting prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. No drug in this class is approved to treat patients with dementia-related psychosis.
Four six-week controlled studies of adults with schizophrenia demonstrated the effectiveness and safety of Latuda. In the trials, patients treated with Latuda had fewer symptoms of schizophrenia than those taking an inactive pill (placebo).
The most common adverse reactions reported by those in clinical trials were drowsiness, feelings of restlessness and the urge to move (akathisia), nausea, movement abnormalities such as tremors, slow movement, or muscle stiffness (Parkinsonism), and agitation.
Latuda is manufactured by Sunovion Pharmaceuticals Inc. of Fort Lee, N.J.
-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG
www.FayetteFrontPage.com
Twitter: @FayetteFP
Friday, October 29, 2010
FDA approves Latuda to treat schizophrenia in adults
Posted by
Georgia Front Page.com
at
9:06 AM
0
comments
Labels: approval, fayette front page, fda, georgia, georgia front page, latuda, schizophrenia, treatment
Friday, August 14, 2009
FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder
The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat bipolar I disorder in adults, a serious psychiatric disorder that causes shifts in a person's mood, energy, and ability to function.
“Mental illnesses like schizophrenia and bipolar disorder can be devastating to patients and families, requiring lifelong treatment and therapy,” said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “Effective medicines can help people with mental illness live more independent lives.”
The most common symptoms of schizophrenia include hearing voices, or seeing things that are not there, having false beliefs (for example, believing that others are controlling thoughts, reading minds, or plotting harm), and being inappropriately suspicious or paranoid. These thoughts may be terrifying and can cause fearfulness, withdrawal, agitation or violence.
Bipolar I disorder is a chronic, severe, and recurrent psychiatric disorder that causes alternating periods of depression and high, increased activity and restlessness, racing thoughts, talking fast, impulsive behavior, and a decreased need for sleep.
Saphris is in a class of drugs called atypical antipsychotics. All atypical antipsychotics contain a boxed warning, the FDA’s strongest warning. The warning alerts prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis (a brain disorder that lessens the ability to remember, think, and reason). Saphris is not approved for these patients.
The efficacy of Saphris in treating schizophrenia was studied in three short-term placebo-controlled and active-drug controlled clinical trials. In two of the trials Saphris demonstrated superior efficacy compared to an inactive pill (placebo) in reducing the symptoms of schizophrenia.
The efficacy of Saphris in the treatment of bipolar disorder was studied in two short-term placebo-controlled and active-drug controlled clinical trials in which Saphris was shown to be superior to placebo in treating symptoms of bipolar disorder.
The most common adverse reactions reported by patients in clinical trials being treated for schizophrenia with Saphris were the inability to sit still or remain motionless (akathisia), decreased oral sensitivity (oral hypoesthesia) and drowsiness (somnolence).
The most common adverse reactions reported by patients in clinical trials using Saphris to treat bipolar disorder were drowsiness, dizziness, movement disorders other than akathisia and weight increase.
Saphris is manufactured by Schering-Plough, Kenilworth, N.J.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
11:30 AM
0
comments
Labels: antipsychotic, approval, atlanta, bipolar, drug treatment, fayette front page, fda, georgia, georgia front page, mental illness, saphris, schizophrenia
Thursday, May 7, 2009
FDA Approves Fanapt to Treat Schizophrenia
The U.S. Food and Drug Administration has approved Fanapt tablets (iloperidone) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder.
"Schizophrenia can be a devastating illness requiring lifelong treatment and therapy," said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. "Medications for schizophrenia can ease many symptoms, allowing people to live more independent lives."
Schizophrenia affects about 1 percent of the U.S. adult population, ages 18 and older, in a given year. The most prominent symptoms include hallucinations, delusions, disordered thinking and behavior, and abnormal expression of emotions. Hearing voices that other people don't hear is the most common type of hallucination. These experiences can make people with the disorder fearful and withdrawn.
Fanapt is included in the atypical antipsychotic class of drugs. All atypical antipsychotics contain a boxed warning, the FDA’s strongest warning. The warning alerts prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. Fanapt is not approved for patients with dementia-related psychosis.
Fanapt demonstrated efficacy in two placebo-controlled short-term clinical trials. In both, Fanapt was superior to placebo (sugar pill) in reducing the symptoms of schizophrenia.
The most common adverse reactions reported by patients using Fanapt in clinical trials were dizziness, dry mouth, fatigue, nasal congestion, sudden fall in blood pressure causing light-headedness upon standing (orthostatic hypotension), drowsiness, rapid heart rate (tachycardia) and weight increase.
Fanapt is manufactured by Patheon Inc. of Mississauga, Ontario, for Vanda Pharmaceuticals Inc., Rockville, Md.
-----
Follow on Twitter @GAFrontPage
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia
Posted by
Georgia Front Page.com
at
7:06 AM
0
comments
Labels: antipsychotic, atlanta, drug approval, fanapt, fayette front page, fda, georgia, georgia front page, schizophrenia, treatment
Tuesday, November 11, 2008
Study Focuses on Teens at Risk for Psychosis
Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder. The five-year, $25-million study joins the resources of Emory and seven other major research universities, with the goal of identifying more precise predictors for psychosis, and a better understanding of the neural mechanisms involved.
"This is a critical, watershed study," said Elaine Walker, Samuel Candler Dobbs Professor of Psychology and Neuroscience at Emory. "To date, no one has systematically studied brain development, patterns of electrical brain activity and changes in gene expression in youth at risk for psychosis."
Schizophrenia, the most extreme psychosis, affects about 1 percent of the population and can have devastating consequences. Most people diagnosed with schizophrenia are unable to hold a job or live independently for most of their lives. They often suffer from homelessness, major depression and anxiety disorders.
"Because schizophrenia is severely debilitating, usually chronic and very costly, preventing its onset has become a major area of emphasis of the NIMH," said Walker, who has studied the origins and precursors of psychosis for 30 years.
Early Diagnosis Critical for Teens
The typical onset of schizophrenia and other psychotic disorders is about 21 years of age, with warning signs beginning, on average, around age 17. Studies have shown that about 30 to 40 percent of prodromal teenagers – those showing warning signs – will develop schizophrenia or another psychotic disorder. About 25 percent of the prodromal teens continue to experience mild symptoms without getting worse, while the remaining 35 percent get better as they enter adulthood.
"We are hoping to get to the point where we can identify people who will cross the threshold into psychosis with 85 to 95 percent accuracy, instead of 30 to 40 percent," Walker said. "Evidence has been accumulating that, not only are there brain abnormalities in people with psychotic disorders, the brain abnormalities get worse the longer the patient goes untreated."
While anti-psychotic drugs can be effective, they also have serious side effects, so physicians are hesitant to recommend them until someone enters the clinical stages of psychosis.
Stress Hormones May Hold Key for Treatment
Walker recently completed a study that tracked changes in the stress hormone cortisol over several years in prodromal teenagers. The results found much sharper increases in cortisol levels in the participants who were eventually diagnosed with a psychosis. "This suggests that youth who are vulnerable to psychosis may be especially sensitive to elevations in cortisol selection," Walker said.
One hypothesis of the NIMH study is that changes in stress hormones that occur in at-risk adolescents are influencing gene expression in the brain. "All neurons in the brain have receptors for hormones and research on animals has shown that cortisol can change how these neurons function," Walker said. "If our theory is right, and we can identify what's going on with this process, it's possible that we could eventually modify cortisol secretion in a way that buffers teenagers against its effects, and gets them through this critical risk period."
Each of the eight institutions involved in the NIMH study will recruit 100 prodomal teenagers and 50 controls to participate in the project. Participants will undergo regular diagnostic interviews, measurements of their cortisol levels, magnetic resonance imaging (MRI) to observe physical development of their brains, and electroencephalography (EEG) to measure neural electrical activity. In addition, the researchers will regularly collect and compare genetic data of the participants.
Researchers are now undergoing training in the study protocol, to ensure data standardization. In January, recruitment for participants will begin. In addition to Emory, the institutions involved are: Harvard, Yale, UCLA, UC-San Diego, Einstein Medical College and the University of Calgary.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
9:21 AM
0
comments
Labels: atlanta, cortisol, emory university, fayette, fayette front page, fayetteville, georgia, georgia front page, mental health, peachtree city, prodromal, psychotic disorder, research, schizophrenia
Friday, July 4, 2008
Violence Declines with Medication Use in Some with Schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
"This is the first large randomized controlled study to compare the effectiveness of several commonly-prescribed medications for schizophrenia on reducing community violence," said Jeffrey Swanson, professor in psychiatry and behavioral sciences and the study's lead author. "Serious violent behavior is not frequent among people with schizophrenia, but when it does occur, the results can be costly and tragic."
The study found that violence declined significantly when patients took antipsychotic medications as prescribed, but only among patients whose prior risk for violence could be linked to psychotic symptoms.
The researchers identified a subgroup of schizophrenia patients with a history of childhood conduct problems who were more likely to be violent at the beginning of the study. Among these patients, violence was not strongly related to psychotic symptoms, and did not significantly decline with adherence to prescribed antipsychotic medication during the six-month study period.
The new results, which are from the National Institute of Mental Health's Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, are published in the July issue of The British Journal of Psychiatry.
"In the past, we've not understood very well why a small proportion of patients with schizophrenia become seriously violent, while most do not--and why medication seems to prevent violent behavior in some and not others," said Marvin Swartz, professor of psychiatry and coauthor of the study. "These findings tell us that people with schizophrenia may behave violently for reasons not directly related to their mental illness. If that's the case, then treatment for psychotic symptoms alone may not eliminate the risk of violence."
Researchers found that a number of factors contributed to violent acts independently of the person's schizophrenia. In addition to childhood conduct problems, substance abuse, being the victim of past violent acts, poverty and living with others, rather than alone, were all predictors of violent behavior.
Medication is the primary course of schizophrenia treatment to reduce symptoms and hopefully prevent violent acts. This study found that newer antipsychotics are as effective as older medications in reducing violence among people with schizophrenia.
"Contrary to the expectations of many clinicians and some research, this study found no benefit for newer medications over an older medication in reducing the risk for violence over the six-month study period," Swanson said. "In fact, one of the newer medications, quetiapine, performed worse than the first-generation drug perphenanize."
The CATIE study included 1,445 patients with schizophrenia who were randomly assigned to treatment with one of five antipsychotic medications, including olanzapine, perphenanize, quetiapine, risperidone, or ziprasidone.
"Antipsychotic drugs may help reduce violence risk, but they don't address all of the causes of violent behavior and they don't help at all if people can't or won't take the medication prescribed. We also need interventions to help patients stay engaged in treatment," Swartz added.
The study's co-authors include Richard A. Van Dorn, Ph.D., Joseph P. McEvoy, M.D., and H. Ryan Wagner, Ph.D., of Duke University Medical Center, Jan Volavka, M.D., Ph.D., of New York University, John Monahan, Ph.D., of the University of Virginia, T. Scott Stroup, M.D., M.P.H., and Eric B. Elbogen, Ph.D., of University of North Carolina at Chapel Hill and Jeffrey A. Lieberman, M.D., of Columbia University for the CATIE Investigators.
Posted by
Georgia Front Page.com
at
7:24 AM
0
comments
Labels: brooks, fayette, fayette county, fayette front page, fayetteville, peachtree city, schizophrenia, tyrone, violence, woolsey